Skip to main content
. Author manuscript; available in PMC: 2017 Jul 11.
Published in final edited form as: Am J Transplant. 2015 Feb 12;15(3):815–822. doi: 10.1111/ajt.13045

Figure 1. Adding atacicept to AMR inducing regimen marginally prolongs graft survival.

Figure 1

(A) AMR dosing strategy and additional atacicept treatment are represented. Atacicept (TACI-Ig) was added to the AMR regimen, administered subcutaneously weekly for a month. Five animals received the AMR regimen, which includes CD3-immunotoxin, alefacept, and tacrolimus (trough 8–12 ng/mL). Three animals received the AMR regimen plus additional atacicept for 4 weeks (duration and frequency indicated by blue arrows along the x-axis). (B) Serum BAFF level from AMR control and additional atacicept treatment are represented. (C) Additional atacicept treated animals have a marginally prolonged graft survival (MST 101 days; p=0.1) compared to AMR controls (MST=56 days).